Research and Markets (http://www.researchandmarkets.com/research/dbe80f/china_pharmaceutic) has announced the addition of the "China Pharmaceuticals and Healthcare Report Q4 2009" report to their offering.
The China Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on China's pharmaceuticals and healthcare industry.
In BMI's view, China is arguably the most attractive emerging pharmaceutical market. Though to 2013, we are forecasting a compound annual growth rate (CAGR) of 15.45%. Annual per-capita spending will rise from US$27.60 to US$54.40. Spending as a percent of GDP is expected to increase from 0.97% to 1.16%. Key drivers of market expansion are the introduction of universal health insurance, a booming economy, more chronic diseases, and an ageing population. By 2018, annual pharmaceutical sales will have reached a staggering US$132.7bn.